were purchased from commercial sources and were used without further
purification. 3,4-Diethoxycyclobut-3-ene-1,2-dione (95%, ABCR), zinc
trifluoromethanesulfonate (98%, Sigma-Aldrich), 4-vinylaniline (97%,
Sigma-Aldrich), 2-aminoethyl methacrylate hydrochloride (90%, Sigma-Aldrich), N,N-diisopropylethylamine (DIPEA, >99%,
Sigma-Aldrich), N,N-dimethylacrylamide
(DMAAm, 99%, Sigma-Aldrich), ethylene glycol dimethacrylate (EGDMA,
98%, Sigma-Aldrich), 2,2′-azobis(2-methylpropionitrile) (AIBN,
98%, Sigma-Aldrich), tetrabutylammonium fluoride hydrate ([Bu4N]+[F]−, 98%, ABCR), tetrabutylammonium
chloride ([Bu4N]+[Cl]−, >97%,
Sigma-Aldrich), tetrabutylammonium bromide ([Bu4N]+[Br]−, >98%, Sigma-Aldrich), tetrabutylammonium
iodide ([Bu4N]+[I]−, 98%,
Sigma-Aldrich), and tetrabutylammonium acetate ([Bu4N]+[AcO]−, 95%, ABCR) were used as received.
AIBN was recrystallized from methanol prior to use and stored below
5 °C. To remove the residual inhibitor, the main monomer DMAAm
was destabilized via a short column of basic alumina prior use.